FIG 1.

R2-CHOP and placebo/R-CHOP CONSORT diagram (flow of patients from screening to analysis). ^aMain reasons for failing eligibility criteria: 8% inadequate lymph node or biopsy specimen available, 5% not Ann Arbor stage II-IV, 4% not International Prognostic Index ≥ 2, and 3% unable to adhere to protocol requirements. ^bTwo R2-CHOP and one placebo/R-CHOP patients were randomly assigned, but never received lenalidomide/placebo or R-CHOP. ABC, activated B-cell-like; ITT, intention to treat; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP.